The global market for Latent Tuberculosis Infection Detection was estimated at US$1.8 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 3.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Latent Tuberculosis Infection Detection market.
The increasing incidence of TB globally, particularly in developing countries with limited healthcare infrastructure, has spurred the demand for advanced LTBI detection methods. While traditional skin tests have been the standard, newer blood-based tests, such as the interferon-gamma release assays (IGRAs), are gaining popularity due to their greater accuracy and ability to provide quicker results. Accurate detection of LTBI is essential for controlling the spread of TB and for initiating timely treatment to prevent the development of active TB.
Newer blood tests, such as the QuantiFERON-TB Gold test, are also improving detection by offering a more reliable method for diagnosing LTBI compared to the tuberculin skin test (TST), which can be influenced by factors such as prior BCG vaccination. Furthermore, the integration of digital health tools and telemedicine into the diagnostic process is expanding the reach and efficiency of LTBI testing. These advancements are making it easier to identify individuals who are at risk for progressing to active TB, ultimately helping reduce the global burden of TB.
Furthermore, as governments and health organizations intensify efforts to eliminate TB by targeting latent infections, there is greater emphasis on early diagnosis and treatment. Advancements in diagnostic technology, such as blood-based tests and molecular diagnostics, are improving the speed and accuracy of LTBI detection, making them more accessible and affordable for high-risk populations. The expansion of global health initiatives and funding aimed at TB eradication is further propelling market growth, ensuring that LTBI detection is an integral part of global TB control programs.
Segments: Brand (QFT-Plus Brand, Other Brands); Test Type (Tuberculin Skin Test Type, Interferon Gamma Released Assay Test Type); End-Use (Diagnostic Laboratories End-Use, Hospitals/clinics End-Use, Academic & Research Institutions End-Use); Application (Household Contacts with Pulmonary TB Application, PLHIV Application, Other Applications)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Latent Tuberculosis Infection Detection Market - Key Trends & Drivers Summarized
What Is Latent Tuberculosis Infection (LTBI) and Why Is Early Detection Critical?
Latent Tuberculosis Infection (LTBI) occurs when a person is infected with the tuberculosis (TB) bacteria but does not exhibit active symptoms or show signs of disease. People with LTBI are not contagious, but they are at risk of developing active TB, especially if their immune system becomes weakened. Early detection and treatment of LTBI are crucial to prevent the progression to active TB, which can cause serious health complications and be transmitted to others. The diagnostic process for LTBI typically involves skin tests or blood tests that detect the presence of the TB bacteria in the body.The increasing incidence of TB globally, particularly in developing countries with limited healthcare infrastructure, has spurred the demand for advanced LTBI detection methods. While traditional skin tests have been the standard, newer blood-based tests, such as the interferon-gamma release assays (IGRAs), are gaining popularity due to their greater accuracy and ability to provide quicker results. Accurate detection of LTBI is essential for controlling the spread of TB and for initiating timely treatment to prevent the development of active TB.
How Are Advancements in Diagnostic Technologies Impacting the LTBI Detection Market?
Advancements in diagnostic technologies have significantly improved the accuracy, speed, and accessibility of LTBI detection. Molecular diagnostics, such as PCR-based tests, are increasingly being used to detect TB bacteria at an early stage, providing faster results and greater sensitivity compared to traditional methods. Additionally, the development of portable and point-of-care diagnostic tools is improving access to LTBI testing, particularly in remote or resource-limited settings where laboratory infrastructure may be lacking. These innovations are crucial for identifying LTBI in populations that are at high risk for TB, such as healthcare workers, individuals living with HIV, and those in close contact with active TB patients.Newer blood tests, such as the QuantiFERON-TB Gold test, are also improving detection by offering a more reliable method for diagnosing LTBI compared to the tuberculin skin test (TST), which can be influenced by factors such as prior BCG vaccination. Furthermore, the integration of digital health tools and telemedicine into the diagnostic process is expanding the reach and efficiency of LTBI testing. These advancements are making it easier to identify individuals who are at risk for progressing to active TB, ultimately helping reduce the global burden of TB.
What Are the Primary Drivers of the LTBI Detection Market`s Growth?
The primary drivers behind the growth of the LTBI detection market are the increasing global prevalence of tuberculosis and the need for more accurate, efficient detection methods. As TB remains a major public health concern, particularly in low-income and middle-income countries, there is growing demand for reliable and cost-effective diagnostic tools to identify LTBI early. The rise in global migration, particularly from regions with high TB prevalence, is also contributing to the increased demand for LTBI screening and detection.Furthermore, as governments and health organizations intensify efforts to eliminate TB by targeting latent infections, there is greater emphasis on early diagnosis and treatment. Advancements in diagnostic technology, such as blood-based tests and molecular diagnostics, are improving the speed and accuracy of LTBI detection, making them more accessible and affordable for high-risk populations. The expansion of global health initiatives and funding aimed at TB eradication is further propelling market growth, ensuring that LTBI detection is an integral part of global TB control programs.
What Are the Key Growth Drivers for the LTBI Detection Market?
The growth in the LTBI detection market is driven by several factors, including the increasing incidence of tuberculosis globally, the rising demand for faster and more accurate diagnostic methods, and growing awareness about the importance of detecting and treating LTBI to prevent the spread of TB. The expansion of global health programs aimed at TB eradication, along with advancements in diagnostic technologies, is providing greater access to early detection methods. Additionally, the increasing movement of people across borders and the greater emphasis on preventive healthcare are also driving the demand for LTBI testing worldwide. As countries continue to prioritize TB control, the demand for effective LTBI detection and screening will continue to grow, ensuring that the fight against tuberculosis remains at the forefront of global health efforts.Report Scope
The report analyzes the Latent Tuberculosis Infection Detection market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Brand (QFT-Plus Brand, Other Brands); Test Type (Tuberculin Skin Test Type, Interferon Gamma Released Assay Test Type); End-Use (Diagnostic Laboratories End-Use, Hospitals/clinics End-Use, Academic & Research Institutions End-Use); Application (Household Contacts with Pulmonary TB Application, PLHIV Application, Other Applications)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the QFT-Plus Brand segment, which is expected to reach US$1.4 Billion by 2030 with a CAGR of a 3.0%. The Other Brands segment is also set to grow at 4.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $487.6 Million in 2024, and China, forecasted to grow at an impressive 6.6% CAGR to reach $441.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Latent Tuberculosis Infection Detection Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Latent Tuberculosis Infection Detection Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Latent Tuberculosis Infection Detection Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, ARKRAY, Inc., Becton, Dickinson and Company (BD), Beijing Wantai Biological Pharmacy, bioMérieux S.A. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 41 Featured):
- Abbott Laboratories
- ARKRAY, Inc.
- Becton, Dickinson and Company (BD)
- Beijing Wantai Biological Pharmacy
- bioMérieux S.A.
- Bio-Rad Laboratories, Inc.
- Cepheid
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Hologic, Inc.
- Lionex GmbH
- Luminex Corporation
- Oxford Immunotec Global PLC
- Par Pharmaceutical, Inc.
- PerkinElmer, Inc.
- QIAGEN N.V.
- Sanofi S.A.
- SD Biosensor, Inc.
- Serum Institute of India Pvt. Ltd.
- Thermo Fisher Scientific Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- ARKRAY, Inc.
- Becton, Dickinson and Company (BD)
- Beijing Wantai Biological Pharmacy
- bioMérieux S.A.
- Bio-Rad Laboratories, Inc.
- Cepheid
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Hologic, Inc.
- Lionex GmbH
- Luminex Corporation
- Oxford Immunotec Global PLC
- Par Pharmaceutical, Inc.
- PerkinElmer, Inc.
- QIAGEN N.V.
- Sanofi S.A.
- SD Biosensor, Inc.
- Serum Institute of India Pvt. Ltd.
- Thermo Fisher Scientific Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 464 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.8 Billion |
| Forecasted Market Value ( USD | $ 2.2 Billion |
| Compound Annual Growth Rate | 3.6% |
| Regions Covered | Global |
